Foundry Therapeutics 1, Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2025 | $45 M | No. 4 | $10 to $50 million | equity, options | SEC | |
| Sep 2021 | $87 M | No. 3 | $50 to $250 million | equity | SEC | |
| Apr 2020 | $15 M | No. 2 | $10 to $50 million | debt, options | SEC | |
| Jan 2019 | $16 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Foundry Therapeutics 1, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2025).
SEC Form D · Feb 2025
The industry group it chose in its notices: Other Technology.
SEC Form D · Feb 2025
That is all the official record says: Foundry Therapeutics 1, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Foundry Therapeutics 1, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 22 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Adam A. Gridley | Executive officer | Feb 2025 |
| Kristen A. Howells | Executive officer | Feb 2025 |
| Adam J. Gridley | Executive officer | Sep 2021 |
| Adam D. Gridley | Executive officer | Jul 2021 |
| Karun D. Naga | Executive officer | May 2020 |
| Mark A. Deem | Executive officer | Feb 2019 |
| Adam A. Gridley | Director | Feb 2025 |
| Anselm A. Tan | Director | Feb 2025 |
| J.C. A. Lopez | Director | Feb 2025 |
| Leighton A. Read | Director | Feb 2025 |
| Mark A. Deem | Director | Feb 2025 |
| Michael A. Carusi | Director | Feb 2025 |
| Nicole A. Vitullo | Director | Feb 2025 |
| Paul A. McCreadie | Director | Feb 2025 |
| Tiffany A. Le | Director | Feb 2025 |
| Josh A. Makower | Director | Dec 2023 |
| Tak A. Cheung | Director | Dec 2023 |
| Adam J. Gridley | Director | Sep 2021 |
| Josh J. Makower | Director | Sep 2021 |
| Leighton J. Read | Director | Sep 2021 |
| Nicole J. Walker | Director | Sep 2021 |
| Paul J. McCreadie | Director | Sep 2021 |
| Tak J. Cheung | Director | Sep 2021 |
| Adam D. Gridley | Director | Jul 2021 |
| Josh D. Makower | Director | Jul 2021 |
| Karun D. Naga | Director | Jul 2021 |
| Leighton D. Read | Director | Jul 2021 |
| Tak D. Cheung | Director | Jul 2021 |
| Hanson S. Gifford III | Director | May 2020 |